Article
Reduced viral fitness and lack of cross-class resistance with integrase strand transfer inhibitor and nucleoside reverse transcriptase inhibitor resistance mutations.
Antimicrobial agents and chemotherapy - 1 Jan 2015
Andreatta Kristen N, Goodman Derrick D, Miller Michael D, White Kirsten L
Abstract excerpt
The most common pattern of emergent resistance in the phase III clinical trials of coformulated elvitegravir (EVG)-cobicistat (COBI)-emtricitabine (FTC)-tenofovir disoproxil fumarate (TDF) was the EVG resistance substitution E92Q in integrase (IN) with the FTC resistance substitution M184V in reverse transcriptase (RT), with or without the tenofovir (TFV) resistance substitution K65R. In this study, the effect of...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
